Malignancies in Prader-Willi syndrome: results from a large international cohort and literature review
File(s)dgad312.pdf (545.74 KB)
Published version
Author(s)
Type
Journal Article
Abstract
CONTEXT: Prader-Willi syndrome (PWS) is a complex disorder combining hypothalamic dysfunction, neurodevelopmental delay, hypotonia, and hyperphagia with risk of obesity and its complications. PWS is caused by the loss of expression of the PWS critical region, a cluster of paternally expressed genes on chromosome 15q11.2-q13. As life expectancy of patients with PWS increases, age-related diseases like malignancies might pose a new threat to health. OBJECTIVE: To investigate the prevalence and risk factors of malignancies in patients with PWS and to provide clinical recommendations for cancer screening. METHODS: We included 706 patients with PWS (160 children, 546 adults). We retrospectively collected data from medical records on past or current malignancies, the type of malignancy and risk factors for malignancy. Additionally, we searched the literature for information about the relationship between genes on chromosome 15q11.2-q13 and malignancies. RESULTS: Seven adults (age range 18-55 years old) had been diagnosed with a malignancy (acute lymphoblastic leukemia, intracranial hemangiopericytoma, melanoma, stomach adenocarcinoma, biliary cancer, parotid adenocarcinoma and colon cancer). All patients with a malignancy had a paternal 15q11-13 deletion. The literature review showed that several genes on chromosome 15q11.2-q13 are related to malignancies. CONCLUSION: Malignancies are rare in patients with PWS. Therefore, screening for malignancies is only indicated when clinically relevant symptoms are present such as unexplained weight loss, loss of appetite, symptoms suggestive of paraneoplastic syndrome, or localizing symptoms. Given the increased cancer risk associated with obesity, which is common in PWS, participation in national screening programs should be encouraged.
Date Issued
2023-12-01
Date Acceptance
2023-05-26
Citation
Journal of Clinical Endocrinology and Metabolism, 2023, 108 (12), pp.e1720-e1730
ISSN
0021-972X
Publisher
Oxford University Press
Start Page
e1720
End Page
e1730
Journal / Book Title
Journal of Clinical Endocrinology and Metabolism
Volume
108
Issue
12
Copyright Statement
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered
or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered
or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/37267430
PII: 7189787
Subjects
Comorbidity[Mesh]
Hypothalamo-Hypophyseal System[Mesh]
Neoplasms[Mesh]
Prader-Willi Syndrome[Mesh]
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2023-06-02